Cardio Diagnostics Holdings, Inc. reports developments in precision cardiovascular medicine, including AI-driven genetic and epigenetic blood tests for coronary heart disease. The company’s commercial products include Epi+Gen CHD, which assesses three-year risk for a coronary heart disease event, and PrecisionCHD, which aids in CHD diagnosis and management.
Recurring updates include clinical data for cardiovascular disease detection, CMS reimbursement and MolDX payment-rate activity, provider-network expansion, community health partnerships, and commercialization efforts for physician-ordered testing. Company communications also describe its Integrated Genetic-Epigenetic Engine and broader cardiovascular disease prevention, detection, and management strategy.
Cardio Diagnostics (CDIO) will host an investor call on December 10, 2026, covering coronary disease detection and international testing updates. The call begins at 11 a.m. Central Time. Management will present data supporting its technology’s ability to detect non-obstructive coronary artery disease, disease without severe blockages in major arteries, using a blood sample.
The company plans to pursue FDA Breakthrough Device designation for this use and discuss the anticipated timing of its request. Designation, if granted, offers prioritized review and more interactive FDA engagement during development. Management will also discuss the commencement of testing in India, its first international market, with Dr. Lal PathLabs and Aimil. Other topics include its commercially available tests, ongoing and planned studies, and reimbursement progress.
Cardio Diagnostics Holdings (Nasdaq: CDIO) released a whitepaper examining gaps in detecting coronary disease in patients without significant large-artery blockages.
The paper addresses non-obstructive coronary artery disease (NOCAD), which describes patients with coronary disease symptoms but no significant blockage in the large coronary arteries. It discusses INOCA, a subgroup involving inadequate blood supply without obstructive coronary arteries, and why symptoms can remain unexplained by angiography.
The whitepaper outlines a diagnostic pathway from primary-care assessment to cardiology referral and advanced testing. Cardio Diagnostics says epigenetics-based testing may help identify INOCA earlier and describes this as a potential application of PrecisionCHD, its AI- and epigenetics-based blood test that aids coronary heart disease diagnosis.
Cardio Diagnostics (Nasdaq: CDIO) released an updated edition of its rural health report, “The State of Rural Hospitals and Cardiovascular Care,” outlining current gaps in rural cardiovascular services and a proposed roadmap for improvement. The report highlights severe workforce shortages, noting that 46% of U.S. counties have no practicing cardiologist and rural areas have 39.8 physicians per 100,000 residents versus 53.3 in urban areas. It also cites access issues, with 28% of rural Americans lacking broadband, limiting telehealth and remote monitoring adoption.
The report emphasizes that rural populations face higher cardiovascular disease risk due to isolation, lower socioeconomic status, less preventive care, and higher smoking rates (23.3% rural vs. 15.5% urban). Cardio Diagnostics presents a four-part model for improving rural CVD care: upskilling primary care clinicians, using epigenetic-genetic testing, implementing population-wide health strategies, and integrating remote care options.
Cardio Diagnostics (Nasdaq: CDIO) has begun in-house processing at its new high-complexity, CLIA-certified laboratory in Iowa City, Iowa, gaining end-to-end control over its multi-omics cardiovascular tests, Epi+Gen CHD™ and PrecisionCHD™. The lab was staffed, equipped, and licensed within a year, receiving its federal CLIA license with no deficiencies and securing additional state licenses in California, Maryland, Rhode Island, and Pennsylvania, while pursuing New York certification. In-house operations replace prior third-party processing, aiming to improve cost control, unit economics, and test margins, with the company expecting approximately 40% gross margins at scale. The facility currently offers a 7–10 business day turnaround from sample receipt and includes a research lab focused on precision epigenetic monitoring to support more targeted cardiovascular care.
Cardio Diagnostics (Nasdaq: CDIO) will host an investor conference call on Thursday, August 20, 2026, at 3 p.m. Central Time. The call will cover its precision molecular approach to cardiovascular disease, updates on Epi+Gen CHD and PrecisionCHD tests, ongoing and planned studies, reimbursement progress, and strategic growth initiatives. Investors can join via webcast or telephone, with a replay available after the event.
Cardio Diagnostics (Nasdaq: CDIO) announced that Atlas Healthcare Physicians (AHP), a Southern California independent physician association, will cover its Epi+Gen CHD and PrecisionCHD blood tests with prior authorization starting May 2026.
The tests assess three-year coronary heart disease risk and aid CHD diagnosis without radiation, fasting, or special infrastructure, supporting earlier detection and personalized cardiovascular care across AHP’s Los Angeles and Orange County network.
Cardio Diagnostics (Nasdaq: CDIO) will showcase its precision cardiovascular solutions at four national benefits conferences in June 2026. The company will engage employers, brokers, unions, and plan administrators on using its blood tests and analytics platform to address cardiovascular disease, a major benefits cost driver.
Offerings include clinically validated tests Epi+Gen CHD, PrecisionCHD, and the HeartRisk population insights platform, aimed at identifying at-risk individuals earlier, supporting preventive care, and helping reduce direct and indirect cardiovascular-related costs for health plans and workforces.
Cardio Diagnostics (Nasdaq: CDIO) will host an investor conference call on Thursday, February 19, 2026 at 3:00 p.m. Central Time.
The call will review the company’s precision molecular approach, updates on commercially available tests Epi+Gen CHD™ and PrecisionCHD™, recent breakthrough clinical data, reimbursement progress, and strategic growth initiatives. A webcast and replay are available.
Cardio Diagnostics (Nasdaq: CDIO) will host an investor conference call on Wednesday, February 18, 2026 at 3:00 p.m. Central Time to review its precision molecular approach to cardiovascular disease prevention and early detection.
The call will cover commercial tests Epi+Gen CHD and PrecisionCHD, recent breakthrough clinical data, reimbursement progress, and strategic growth initiatives. A live webcast and dial-in access are provided; a replay will be available after the call.
Cardio Diagnostics (NASDAQ: CDIO) announced a strategic agreement with Aimil and Dr. Lal PathLabs to launch the PrecisionCHD™ blood test in India. This marks Cardio Diagnostics’ first expansion outside the United States and targets earlier detection and personalized management of coronary heart disease (CHD).
PrecisionCHD combines epigenetics, genetics and AI to detect obstructive and non‑obstructive CHD, including INOCA and MINOCA; supporting data were presented at the American Heart Association Scientific Sessions. Initial integration into Dr. Lal PathLabs’ network (290+ labs, 300+ MD pathologists) has begun, with commercial rollout expected in 2026.